Clinical Study
Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population
Table 3
Patient pharmacokinetic parameters when two concentrations were available.
| ā | Elimination rate (Hā1) | Volume of distribution (L/kg) | Half-life (Hrs) | (mg/dL) | (mg/dL) |
| Patient 1 | 0.149 | 0.23 | 4.6 | 19.6 | 0.6 | Patient 2 | 0.156 | 0.29 | 4.4 | 16.8 | 0.4 | Patient 3 | 0.158 | 0.29 | 4.4 | 22.6 | 0.5 |
|
|